| Species |
Human |
| Protein Construction |
| hFc |
TGF-alpha (Val40-Ala89)_x000D_
Accession # P01135-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TGF-alpha hFc Chimera, Human at 0.2μg/ml (100μl/well) on the plate can bind Biotinylated AntiTGFalpha Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
32.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 50mM Tris,100mM NaCl (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Transforming growth factor-alpha (TGFA) has been proposed as a candidate gene in the etiology of nonsyndromic cleft lip with or without cleft palate (NS-CL/P) and of nonsyndromic cleft palate only (NS-CPO). Biologic support for a role of TGFA arises from its presence at high levels in the epithelial tissue of the medial edge of the palatal shelves at the time of shelf fusion in mice. |
| Synonyms |
ETGF; TGF-alpha; TGF type 1; TGFA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
